Table 2 Responses.

From: Prognostic impact of ASXL1 mutations in chronic phase chronic myeloid leukemia

Response

ASXL1 (N = 9)

Other mutations (N = 13)

No Mutation (N = 48)

N (%)

Median TTRa (range)

P

N (%)

Median TTRa (range)

P

N (%)

Median TTRa (range)

MCyR

9 (100%)

3.3 (1–65)

0.9

12 (92%)

3.7 (1–13)

0.5

45 (94%)

3.4 (1–52)

CCyR

8 (89%)

9.7 (3–66)

0.4

11 (85%)

6.0 (3–13)

0.2

45 (94%)

6.0 (2–31)

MMR

7 (78%)

17.5 (5–66)

0.7

10 (77%)

6.7 (3–70)

0.7

39 (81%)

9.2 (3–142)

MR4

5 (56%)

29.1 (10–86)

0.5

8 (62%)

15.5 (4–76)

0.7

32 (67%)

16.3 (3–167)

MR4.5

4 (44%)

48.7 (11–89)

0.7

8 (62%)

27.0 (12–120)

0.7

26 (54%)

17.2 (4–73)

Early responseb

3/9 (33%)

–

0.3

5/12 (42%)

–

0.2

28/42 (67%)

–

  1. Early response is reported as number/evaluable.
  2. TTR time to response in months, MCyR major cytogenetic response, CCyR complete cytogenetic response, MMR major molecular response, MR4 molecular response with a 4-log reduction, MR4.5 molecular response with a 4.5-log reduction.
  3. aWilcoxon rank sum test was performed to assess the difference in TTR (*P < 0.05).
  4. bDefined as BCR::ABL1 < 10% at 3 months.
Back to article page